Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CLK3 | P49761 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29172743 | 0.70 | ALDH1A1 (0.31) | — | |
| SCHEMBL20740567 | 0.69 | CDK5 (0.42) | CSNK1ECLK1CLK2CLK3GSK3B | |
| SCHEMBL28922229 | 0.68 | CASR (0.31) | CDK6CDK4 | |
| SCHEMBL8422995 | 0.67 | — | — | |
| SCHEMBL11057987 | 0.66 | — | — | |
| SCHEMBL29893529 | 0.66 | KDM4E (0.33) | — | |
| SCHEMBL30048707 | 0.65 | — | — | |
| SCHEMBL21927511 | 0.64 | CDK5 (0.45) | CSNK1ECLK1CLK2CLK3GSK3B | |
| SCHEMBL31526577 | 0.63 | EGFR (0.30) | — | |
| SCHEMBL11065399 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3444246-B1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | SHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-10464927-B2 | 2,4-disubstituted pyrimidines as CDK inhibitors | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2019-11-05 | — | — | US | disclosed |
| US-20190071427-A1 | 2,4-Disubstituted Pyrimidine Derivative as CDK Inhibitor and Use Thereof | CHENGDU JINRUI FOUNDATION BIOTECH CO., LTD. (CN) | 2019-03-07 | — | — | US | disclosed |
| EP-3444246-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | Shanghai Xunhe Pharmaceutical Technology Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071427-A1 | 2,4-Disubstituted Pyrimidine Derivative as CDK Inhibitor and Use Thereof | CDK4, CDK2, CDK6 | CSNK1E 142/4885CLK1 1002/4885CLK2 294/4885 |
| US-10464927-B2 | 2,4-disubstituted pyrimidines as CDK inhibitors | CDK4, CDK2, CDK6 | CSNK1E 158/4885CLK1 982/4885CLK2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.